A Safety Study of PF-08046044/SGN-35C in Adults With Advanced Cancers

PHASE1

Phase

TERMINATED

Status

Enrollment

INDUSTRY

Sponsor class

Stopped The trial was terminated for strategic reasons due to portfolio reprioritization. The decision was not based on any safety or regulatory concerns

Conditions

Hodgkin Disease
Lymphoma, T-Cell, Peripheral
Lymphoma, Large B-Cell, Diffuse
Lymphoma, Large-Cell, Anaplastic

Interventions

DRUG: PF-08046044/SGN-35C

Sponsor

Seagen, a wholly owned subsidiary of Pfizer